Gameiro, Sofia R.

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Lind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 247

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 195

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

Hicks, K. C., Chariou, P. L., Ozawa, Y., Minnar, C. M., Knudson, K. M., Meyer, T. J., Bian, J., Cam, M., Schlom, J., & Gameiro, S. R. (2021) · Nature Communications

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 83

Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Fenerty, K. E., Padget, M., Wolfson, B., Gameiro, S. R., Su, Z., Lee, J. H., Rabizadeh, S., Soon-Shiong, P., & Hodge, J. W. (2018) · Journal for ImmunoTherapy of Cancer

Immune Cell Function and InteractionPARP inhibition in cancer therapy

Cited by 68

Cooperative immune-mediated mechanisms of the HDAC inhibitor entinostat, an IL15 superagonist, and a cancer vaccine effectively synergize as a novel cancer therapy

Hicks, K. C., Knudson, K. M., Lee, K. L., Hamilton, D. H., Hodge, J. W., Figg, W. D., Ordentlich, P., Jones, F. R., Rabizadeh, S., Soon-Shiong, P., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 44